Johnson & Johnson said the vaccine batch did not pass quality standards checks, and that the blocking of the production process testifies to the rigorous controls that are applied to each batch. The problem was immediately shared with the Food and Drug Administration (FDA), the US government agency that deals with regulating drugs and food products, which is investigating to find the error.
Johnson & Johnson explained, however, that there have been no delays in the delivery of more than 20 million doses in the United States agreed by the end of March, and that another 24 million doses will be delivered by April.
– Read also: How Johnson & Johnson’s vaccine works
The Emergent Biosolutions facility where the problem was found is located in Baltimore, Maryland, where the company also makes AstraZeneca’s vaccine, as well as Johnson & Johnson’s. Again according to the New York Times, the mistake would have been caused by some workers of the plant, who a few weeks ago would have inadvertently mixed ingredients of the two vaccines.
Get the latest news delivered to your inbox
Follow us on social media networks